A50 may alleviated DOX-induced hepatotoxicity by activating the PI3K/AKT/HO-1 pathway to inhibit oxidative stress-driven pathological processes, including mitochondrial dysfunction, inflammation, and apoptosis.
Abstract
Doxorubicin (DOX) is a broad-spectrum antineoplastic agent with remarkable efficacy against various malignant tumors. However, its clinical application is severely limited by profound hepatotoxicity, wherein oxidative stress acts as a pivotal mechanism underlying DOX-induced hepatotoxicity. N-salicyloyl tryptamine derivatives (NSTs) have been reported to possess potent antioxidant activities. In the present study, NSTs were applied for the first time in DOX-induced hepatotoxicity with structural modifications to the scaffold. Through systematic screening, a novel compound A50 was identified as the most potent active candidate. Both in vitro (AML12 cell lines) and in vivo (mice model of DOX-induced hepatotoxicity) experiments demonstrated that A50 significantly enhanced superoxide dismutase (SOD) activity, reduced malondialdehyde (MDA) levels, stabilized mitochondrial membrane potential (MMP), and promoted adenosine triphosphate (ATP) production, thus effectively improving mitochondrial function and suppressing oxidative stress-mediated damage. Additionally, A50 decreased serum levels of liver injury biomarkers [alanine transaminase (ALT), aspartate transaminase (AST) and levels of proinflammatory cytokines [tumor necrosis factor-αα (TNF-α), interleukin-6 (IL-6)], inhibited lactate dehydrogenase (LDH) activity, and attenuated histopathological lesions in liver tissues, without affecting its anti-hepatocellular carcinoma activity. Mechanism investigations revealed the hepatoprotective effects of A50 were associated with activation of the PI3K/AKT/HO-1 signaling pathway, and these effects could be blocked by the PI3K-specific inhibitor LY294002 in vitro. In conclusion, A50 may alleviated DOX-induced hepatotoxicity by activating the PI3K/AKT/HO-1 pathway to inhibit oxidative stress-driven pathological processes, including mitochondrial dysfunction, inflammation, and apoptosis. These findings highlight A50 as a promising candidate for the treatment of DOX-induced hepatotoxicity.
Targeting ferroptosis has emerged as a promising anti-cancer strategy. A Food and Drug Administration (FDA)-approved drug, sulfasalazine (SAS), also a ferroptosis inducer, is being explored as a potential treatment drug for cancer. However, long-term high-dose SAS treatment may induce several adverse effects in the...
Kai Han, Jia-Yuan Li, Bing-Ying Shuai et al.· Food & Medicine Homology· 0 citations
Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major limitation to the clinical use of DOX, highlighting the need for effective cardioprotective strategies. Although acteoside (ACT), a natural compound with antioxidant properties, has shown potential cardioprotective effects, its role in DIC, particularly in the r...
Meng Wang, Che Wang, Zhi-Hao Liu et al.· European Journal of Pharmaco...· 0 citations
Background
Acetaminophen (APAP) overdose is a leading cause of drug-induced liver injury (DILI). Inspired by the synergistic hepatoprotective effects of (20S, 24R)-ocotillol (OC) and lipoic acid (LA), we designed and synthesized OCLA, a novel ginsenoside derivative that has been granted a patent.
Methods
The structur...
Han Liu, Qiu-Yue Zhang, Wei Shang et al.· Frontiers in Pharmacology· 0 citations
INTRODUCTION
Doxorubicin (Dox) is a widely used antineoplastic drug that often causes cardiomyopathy, leading to congestive heart failure through the production of Reactive Oxygen Species (ROS) within the myocardium. This investigation examines the protective effects of Methyl Jasmonate (MeJA) against Dox-induced cardi...
Ujwal N. Katolkar, S. Surana· Recent advances in inflammat...· 0 citations
The administration of newly synthesized fused azine derivative compounds successfully reduced APAP-induced hepatic fibrosis through decreasing serum liver enzymes, as well as the hepatic pathological deterioration and effectively ameliorated the inflammatory response.
Ahmed Shawky, Heba A. Metwaly, Hanan M. Ragab et al.· Inflammation· 0 citations
BACKGROUND
Doxorubicin (DOX) is an effective antineoplastic agent whose clinical use is limited by hepatotoxicity. This study evaluated the hepatoprotective effects of Olea europaea leaf extract (OLE) in a rat model of DOX -induced hepatotoxicity.
METHODS
Thirty-two male Wistar rats were randomly assigned to four gro...
M. Ibrahim, A. Khalifa, Rania A. Galhom et al.· Tissue & Cell· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.